HAVCR2 and ovarian cancer: The percentage of patients with high TIM‐3 expression in colorectal, breast, and ovarian cancers was not significantly different from those in non‐colorectal, non‐breast, and non‐ovarian cancers, respectively (Table 2, Figure 2).